Search

Your search keyword '"Emi Y"' showing total 34 results

Search Constraints

Start Over You searched for: Author "Emi Y" Remove constraint Author: "Emi Y" Publisher elsevier bv Remove constraint Publisher: elsevier bv
34 results on '"Emi Y"'

Search Results

1. Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial—EPOC 2 (JFMC49-1601-C5)

2. O-11 Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan

3. Fourier-transform microwave spectroscopy of CoNO

4. 1425MO Effects of elemental diet for gastrointestinal adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil (EPOC 2 study: JFMC49-1601-C5): A phase III randomized controlled trial

6. Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial

7. Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B

8. Millimeter- and submillimeter-wave spectroscopy of platinum monocyanide, PtCN

9. A phase II randomized trial of adjuvant chemotherapy for the patients completely resected pathological stage IB (T > 5cm), II, IIIA non-small cell lung cancer comparing S-1 versus S-1 with cisplatin

10. Primary efficacy results and clinical impact of UGT1A1 genotype on safety from a Phase II study of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: The QUATTRO study

11. Rotational spectroscopy of AuH and AuD in the 1Σ+ electronic ground state

12. 189P Phase II trial of S-1 plus panitumumab for wild-type KRAS unresectable colorectal cancer patients previously treated with 5-fluorouracil (5-FU), oxaliplatin and irinotecan (KSCC1103)

13. Updated report: A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402)

14. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)

15. Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study

16. 2137 Comparison of two Phase II trials of mFOLFOX6 plus bevacizumab (KSCC0802) and SOX (S-1 and oxaliplatin) plus cetuximab (KSCC1002): First line chemotherapy in colorectal cancer patients with initially unresectable or not optimally resectable liver only metastases

17. P-244 Prospective study of S-1 + Irinotecan plus bevacizumab as second-line therapy in Japanese patients with metastatic colorectal cancer (KSCC1102)

18. Randomized Phase Ii Study of S-1 Plus Oral Leucovorin (Sl) Versus Sl Plus Oxaliplatin (Sol) Versus S-1 Plus Cisplatin (Sp) in Patients with Advanced Gastric Cancer (Agc):Updated Overall Survival Data

22. Liver Resectability Following MFOLFOX6 with Bevacizumab as the First-Line Treatment of Unresectable Liver Limited Metastases from Colorectal Cancer in Japanese Patients (KSCC 0802)

23. Phase II Study Alternating Mfolfox 6 and Folfiri (FIREFOX) Plus Bevacizumab (BEV) Regimen in First-Line Treatment of Advanced Colorectal Cancer in Japanese Patients (KSCC 0801)

24. Phase II Study of Combination Therapy with S-1 and Cetuximab in Patients with Kras Wild-Type Unresectable Colorectal Cancer, who Had Previously Received Irinotecan, Oxaliplatin, and Fluoropyrimidines (KSCC0901)

Catalog

Books, media, physical & digital resources